RT Journal Article SR Electronic T1 Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 6477 OP 6480 VO 37 IS 11 A1 YUKO OYA A1 TATSUYA YOSHIDA A1 HIROAKI KURODA A1 JUNICHI SHIMIZU A1 YOSHITSUGU HORIO A1 YUKINORI SAKAO A1 TOYOAKI HIDA A1 YASUSHI YATABE YR 2017 UL http://ar.iiarjournals.org/content/37/11/6477.abstract AB Several second-generation inhibitors of anaplastic lymphoma kinase (ALK) have demonstrated potent activity in ALK rearrangement-positive non-small cell lung cancer (NSCLC). Two of these agents, ceritinib, and alectinib, recently received approval for the treatment of ALK-rearranged NSCLC in Japan. The efficacy of treatment with a second-generation ALK inhibitor after failure with a different second-generation ALK inhibitor remains unclear. We present a series of eight patients with ALK-rearranged NSCLC treated with alectinib who experienced disease progression after ceritinib. Both crizotinib and ceritinib were administered to six patients, with four (29%) patients receiving crizotinib followed by ceritinib. Among the eight study patients, two (25%) had partial response, one (12%) stable disease, and five (63%) had progressive disease. The median progression-free survival was 3.6 months (95% confidence interval=0-7.1 months). The results of this study suggest that the second-generation ALK inhibitor alectinib has limited efficacy after initial treatment with the second-generation ALK inhibitor ceritinib.